NCT04293458 - Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE | Biotech Hunter

Enrollment

145

Participants

Timeline

Start Date

February 28, 2020

Primary Completion Date

August 22, 2022

Study Completion Date

August 22, 2022

Conditions

Barrett EsophagusEsophageal AdenocarcinomaBarretts Esophagus With DysplasiaBarrett's Esophagus Without Dysplasia

Interventions

DEVICE

EsoGuard

EsoGuard assay (LDT) will be used on cells collected using EsoCheck (510K cleared esophageal cell collection device) and compared to results of EGD plus biopsies (when taken)

Trial Locations (27)

10016

Lucid Investigative Site, New York

14620

Lucid Investigative Site, Rochester

19107

Lucid Investigative Site, Philadelphia

23249

Lucid Investigative Site, Richmond

23298

Lucid Investigative Site, Richmond

27599

Lucid Investigative Site, Chapel Hill

28040

Lucid Investigative Site, Madrid

29615

Lucid Investigative Site, Greenville

31201

Lucid Investigative Site, Macon

34102

Lucid Investigative Site, Naples

34684

Lucid Investigative Site, Palm Harbor

37212

Lucid Investigative Site, Nashville

37909

Lucid Investigative Site, Knoxville

39232

Lucid Investigative Site, Flowood

47012

Lucid Investigative Site, Valladolid

49519

Lucid Investigative Site, Wyoming

50009

Lucid Investigative Site, Zaragoza

61107

Lucid Investigative Site, Rockford

68124

Lucid Investigative Site, Omaha

70112

Lucid Investigative Site, New Orleans

71105

Lucid Investigative Site, Shreveport

73102

Lucid Investigative Site, Oklahoma City

77030

Lucid Investigative Site, Houston

80113

Lucid Investigative Site, Englewood

83404

Lucid Investigative Site, Idaho Falls

84132

Lucid Investigative Site, Salt Lake City

92868

Lucid Investigative Site, Orange